Cargando…

Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography

BACKGROUND: The present study confirmed the presence and exact range of “vascular normalization window” induced by recombinant human endostatin (RHES) in patients with nasopharyngeal carcinoma (NPC) by analyzing the variation of dynamic contrast-enhanced ultrasonography (DCE-US) quantitative paramet...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhendong, Kang, Min, Zhu, Shangyong, Huang, Jianyuan, Li, Xigui, Wang, Rensheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231431/
https://www.ncbi.nlm.nih.gov/pubmed/30510431
http://dx.doi.org/10.2147/OTT.S181842
_version_ 1783370219640586240
author Yang, Zhendong
Kang, Min
Zhu, Shangyong
Huang, Jianyuan
Li, Xigui
Wang, Rensheng
author_facet Yang, Zhendong
Kang, Min
Zhu, Shangyong
Huang, Jianyuan
Li, Xigui
Wang, Rensheng
author_sort Yang, Zhendong
collection PubMed
description BACKGROUND: The present study confirmed the presence and exact range of “vascular normalization window” induced by recombinant human endostatin (RHES) in patients with nasopharyngeal carcinoma (NPC) by analyzing the variation of dynamic contrast-enhanced ultrasonography (DCE-US) quantitative parameters. Also, the clinical application of DCE-US in the evaluation of vascular normalization was assessed. MATERIALS AND METHODS: A total of 30 previously untreated patients with stage III–IVA NPC were enrolled in the present study and were randomly but equally divided into RHES (endostar [ES]) and normal saline (NS) groups. The patients in the ES group were administered RHES intravenously, while the patients in the NS group were administered normal saline daily for 5 days prior to intensity modulated radiotherapy coupled with concurrent chemotherapy. All patients underwent DCE-US on the day before the administration and on days 3 and 5 subsequently. The Audio Video Interleave of each DCE-US examination was analyzed quantitatively using the CHI-Q software. Several parameters were investigated, such as peak intensity (PI), time to peak (TTP), and mean transit time (MTT). RESULTS: The PI, TTP, and MTT differed significantly at the three time points in the ES group (all P<0.001) but not in the NS group (all P>0.05). In the ES group, PI increased and subsequently decreased, whereas TTP, as well as MTT, lessened initially and then increased within the 5 days after administration of RHES. The maximum value of PI and the minimum value of TTP, as well as MTT, occurred on day 3 (all P<0.05). Furthermore, the values of PI, TTP, and MTT were similar prior to the administration of RHES in both groups (all P>0.05). However, the PI of the ES group was significantly higher (P<0.05), whereas the TTP and the MTT were significantly lower following administration of RHES (all P<0.05) compared with the corresponding parameters of the NS group. CONCLUSION: DCE-US is a suitable method for the clinical evaluation of vascular normalization induced by antiangiogenic agents. The “vascular normalization window” induced by RHES occurs in patients with NPC, and the exact range is within about 5 days post-administration, which contributes towards optimizing the modality of RHES combined with radiotherapy and chemotherapy for NPC patients.
format Online
Article
Text
id pubmed-6231431
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62314312018-12-03 Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography Yang, Zhendong Kang, Min Zhu, Shangyong Huang, Jianyuan Li, Xigui Wang, Rensheng Onco Targets Ther Original Research BACKGROUND: The present study confirmed the presence and exact range of “vascular normalization window” induced by recombinant human endostatin (RHES) in patients with nasopharyngeal carcinoma (NPC) by analyzing the variation of dynamic contrast-enhanced ultrasonography (DCE-US) quantitative parameters. Also, the clinical application of DCE-US in the evaluation of vascular normalization was assessed. MATERIALS AND METHODS: A total of 30 previously untreated patients with stage III–IVA NPC were enrolled in the present study and were randomly but equally divided into RHES (endostar [ES]) and normal saline (NS) groups. The patients in the ES group were administered RHES intravenously, while the patients in the NS group were administered normal saline daily for 5 days prior to intensity modulated radiotherapy coupled with concurrent chemotherapy. All patients underwent DCE-US on the day before the administration and on days 3 and 5 subsequently. The Audio Video Interleave of each DCE-US examination was analyzed quantitatively using the CHI-Q software. Several parameters were investigated, such as peak intensity (PI), time to peak (TTP), and mean transit time (MTT). RESULTS: The PI, TTP, and MTT differed significantly at the three time points in the ES group (all P<0.001) but not in the NS group (all P>0.05). In the ES group, PI increased and subsequently decreased, whereas TTP, as well as MTT, lessened initially and then increased within the 5 days after administration of RHES. The maximum value of PI and the minimum value of TTP, as well as MTT, occurred on day 3 (all P<0.05). Furthermore, the values of PI, TTP, and MTT were similar prior to the administration of RHES in both groups (all P>0.05). However, the PI of the ES group was significantly higher (P<0.05), whereas the TTP and the MTT were significantly lower following administration of RHES (all P<0.05) compared with the corresponding parameters of the NS group. CONCLUSION: DCE-US is a suitable method for the clinical evaluation of vascular normalization induced by antiangiogenic agents. The “vascular normalization window” induced by RHES occurs in patients with NPC, and the exact range is within about 5 days post-administration, which contributes towards optimizing the modality of RHES combined with radiotherapy and chemotherapy for NPC patients. Dove Medical Press 2018-11-08 /pmc/articles/PMC6231431/ /pubmed/30510431 http://dx.doi.org/10.2147/OTT.S181842 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yang, Zhendong
Kang, Min
Zhu, Shangyong
Huang, Jianyuan
Li, Xigui
Wang, Rensheng
Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography
title Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography
title_full Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography
title_fullStr Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography
title_full_unstemmed Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography
title_short Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography
title_sort clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231431/
https://www.ncbi.nlm.nih.gov/pubmed/30510431
http://dx.doi.org/10.2147/OTT.S181842
work_keys_str_mv AT yangzhendong clinicalevaluationofvascularnormalizationinducedbyrecombinanthumanendostatininnasopharyngealcarcinomaviadynamiccontrastenhancedultrasonography
AT kangmin clinicalevaluationofvascularnormalizationinducedbyrecombinanthumanendostatininnasopharyngealcarcinomaviadynamiccontrastenhancedultrasonography
AT zhushangyong clinicalevaluationofvascularnormalizationinducedbyrecombinanthumanendostatininnasopharyngealcarcinomaviadynamiccontrastenhancedultrasonography
AT huangjianyuan clinicalevaluationofvascularnormalizationinducedbyrecombinanthumanendostatininnasopharyngealcarcinomaviadynamiccontrastenhancedultrasonography
AT lixigui clinicalevaluationofvascularnormalizationinducedbyrecombinanthumanendostatininnasopharyngealcarcinomaviadynamiccontrastenhancedultrasonography
AT wangrensheng clinicalevaluationofvascularnormalizationinducedbyrecombinanthumanendostatininnasopharyngealcarcinomaviadynamiccontrastenhancedultrasonography